A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results, and the implications on using ELISA kits for serological studies of Zika virus.
The study by Langerak et al. was published in February 2019, and evaluated the seroprevalence of Zika virus in both urban and rural populations in Suriname during 2017. Participants were tested for the presence of IgG antibodies to ZIKV using both a commercial ELISA kit and a virus neutralisation assay. A key aim of the study was to assess the accuracy of ELISA assays for ZIKV IgG analysis, given previous reports of high levels of cross-reactivity of these assays with Dengue virus in Dengue endemic areas.
Previous studies in Micronesia and French Polynesia had reported seroprevalences of 73% and 49% respectively. However these were carried out with first-generation ELISA assays, and did not use virus neutralisation assays to validate their results. While cross-neutralisation can occur when using from virus neutralisation tests (VNT), they measure functional antibodies that are capable of blocking ZIKV infection of cells and are therefore a more accurate measure of immunity than binding antibodies detected by most ELISAs.
In the Suriname study samples were taken and tested from two cohorts:
44 blood samples were taken from a “pre-ZIKV cohort” (patients presenting with fever between 2012 and 2014, prior to the circulation of ZIKV in Suriname)
770 blood samples were tested during the 2017 outbreak from an urban area and two rural villages in the rainforest.
For the pre-ZIKV cohort, 39 samples (88.6%) tested positive for DENV IgG, and 23 samples (52.3%) tested positive for ZIKV IgG using a commercial ELISA assay. None of the 44 pre-ZIKV samples tested positive for ZIKV by VNT, indicating that there are very high level of cross-reactivity seen with the particular ELISA assay utilised.
For the 2017 cohort, 530 samples (68.8%) tested positive for IgG by ELISA, while only 270 (35.1%) tested positive by VNT.
These results confirm the low specificity of this ZIKV IgG ELISA assay, and may lead to significant over-estimates of ZIKV prevalence if confirmatory tests are not undertaken.
New Generation ELISA Assays: A Solution to Cross-Reactivity
The problem described in this publication can now be overcome with new generation ELISA assays for ZIKV antibodies.
Utilising in-house developed mammalian recombinant proteins, and a novel assay design, The Native Antigen Company has developed a new ZIKV total antibody assay, which demonstrates a dramatic improvement on first generation tests. The total antibody assay has both sensitivity and specificity of >90%, even in Dengue endemic regions. With an assay time of less than 2 hours, and the ability to test samples from any species, this kit presents a new standard for serological studies of ZIKV prevalence.